Which has higher valuation & earnings, LENZ or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENZ Therapeutics $19.09M 8.56 -$82.13M -$3.60 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Does the media prefer LENZ or ATHE?

In the previous week, LENZ Therapeutics had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 7 mentions for LENZ Therapeutics and 4 mentions for Alterity Therapeutics. LENZ Therapeutics' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, ATHE or AARD?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A

Is ATHE or AARD more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Aardvark Therapeutics N/A -61.71% -56.29%

Does the media refer more to ATHE or AARD?

In the previous week, Aardvark Therapeutics had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for Aardvark Therapeutics and 4 mentions for Alterity Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.67 beat Alterity Therapeutics' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aardvark Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ATHE or MENS?

Alterity Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 112.77%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Alterity Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, ATHE or MENS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is ATHE or MENS more profitable?

Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Jyong Biotech N/A N/A N/A

Which has better valuation and earnings, ATHE or CRDL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A

Is ATHE or CRDL more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Cardiol Therapeutics N/A -229.43% -165.60%

Does the media favor ATHE or CRDL?

In the previous week, Alterity Therapeutics and Alterity Therapeutics both had 4 articles in the media. Alterity Therapeutics' average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, MIST or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than Milestone Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Milestone Pharmaceuticals $1.55M 102.01 -$63.06M -$0.68 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is MIST or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -339.33% -61.79% Alterity Therapeutics N/A N/A N/A

Does the media refer more to MIST or ATHE?

In the previous week, Milestone Pharmaceuticals and Milestone Pharmaceuticals both had 4 articles in the media. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Alterity Therapeutics (ATHE) Competitors

$4.70 +0.15 (+3.30%)

Closing price 03:59 PM Eastern

Extended Trading

$4.70 +0.00 (+0.02%)

As of 06:54 PM Eastern

Compare

ATHE vs. LENZ, AARD, MENS, CRDL, and MIST

Should you buy Alterity Therapeutics stock or one of its competitors? Alterity Therapeutics's main competitors and comparable companies include LENZ Therapeutics (LENZ), Aardvark Therapeutics (AARD), Jyong Biotech (MENS), Cardiol Therapeutics (CRDL), and Milestone Pharmaceuticals (MIST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Alterity Therapeutics compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alterity Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. Alterity Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
Alterity Therapeutics	N/A	N/A	N/A

Alterity Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	8.56	-$82.13M	-$3.60	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

LENZ Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

LENZ Therapeutics presently has a consensus target price of $29.80, suggesting a potential upside of 471.98%. Alterity Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 112.77%. Given LENZ Therapeutics' higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, LENZ Therapeutics had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 7 mentions for LENZ Therapeutics and 4 mentions for Alterity Therapeutics. LENZ Therapeutics' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

LENZ Therapeutics and Alterity Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Alterity Therapeutics compare to Aardvark Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

2.1% of Alterity Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Aardvark Therapeutics had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for Aardvark Therapeutics and 4 mentions for Alterity Therapeutics. Aardvark Therapeutics' average media sentiment score of 0.67 beat Alterity Therapeutics' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aardvark Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alterity Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.8, indicating that its share price is 280% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Alterity Therapeutics' return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Aardvark Therapeutics	N/A	-61.71%	-56.29%

Alterity Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 112.77%. Aardvark Therapeutics has a consensus price target of $16.30, indicating a potential upside of 126.70%. Given Aardvark Therapeutics' higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Summary

Alterity Therapeutics and Aardvark Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Alterity Therapeutics compare to Jyong Biotech?

Alterity Therapeutics (NASDAQ:ATHE) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Alterity Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

Alterity Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 112.77%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Alterity Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Jyong Biotech	N/A	N/A	N/A

2.1% of Alterity Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

In the previous week, Alterity Therapeutics had 3 more articles in the media than Jyong Biotech. MarketBeat recorded 4 mentions for Alterity Therapeutics and 1 mentions for Jyong Biotech. Alterity Therapeutics' average media sentiment score of 0.00 equaled Jyong Biotech'saverage media sentiment score.

Company	Overall Sentiment
Alterity Therapeutics	Neutral
Jyong Biotech	Neutral

Summary

Alterity Therapeutics beats Jyong Biotech on 6 of the 8 factors compared between the two stocks.

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Alterity Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

In the previous week, Alterity Therapeutics and Alterity Therapeutics both had 4 articles in the media. Alterity Therapeutics' average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alterity Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alterity Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 112.77%. Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 466.67%. Given Cardiol Therapeutics' higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Alterity Therapeutics beats Cardiol Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Alterity Therapeutics compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Milestone Pharmaceuticals currently has a consensus price target of $7.25, suggesting a potential upside of 470.87%. Alterity Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 112.77%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Milestone Pharmaceuticals is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Milestone Pharmaceuticals and Milestone Pharmaceuticals both had 4 articles in the media. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Milestone Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Alterity Therapeutics has lower revenue, but higher earnings than Milestone Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	102.01	-$63.06M	-$0.68	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Alterity Therapeutics' return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Alterity Therapeutics	N/A	N/A	N/A

Summary

Milestone Pharmaceuticals beats Alterity Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Alterity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHE vs. The Competition

Export

Metric	Alterity Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$41.69M	$11.87B	$7.00B	$12.83B
Dividend Yield	N/A	2.69%	2.58%	10.06%
P/E Ratio	N/A	783.49	268.64	24.76
Price / Sales	N/A	748.15	585.63	95.42
Price / Cash	N/A	15.12	28.89	37.42
Price / Book	1.52	10.16	11.31	6.45
Net Income	-$7.87M	$2.78B	$3.44B	$347.05M
7 Day Performance	7.06%	0.89%	2.27%	0.99%
1 Month Performance	-13.44%	-1.48%	-0.23%	-0.64%
1 Year Performance	-11.65%	182.35%	76.15%	22.27%

Alterity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHE Alterity Therapeutics	3.5245 of 5 stars	$4.70 +3.3%	$10.00 +112.8%	-15.1%	$41.69M	N/A	N/A	10	Analyst Forecast Short Interest Decrease Gap Up
LENZ LENZ Therapeutics	2.2998 of 5 stars	$5.05 +1.2%	$29.80 +490.1%	-84.5%	$156.62M	$19.09M	N/A	110	News Coverage Earnings Report
AARD Aardvark Therapeutics	3.5529 of 5 stars	$7.27 +2.7%	$16.30 +124.2%	-36.9%	$154.94M	N/A	N/A	18	News Coverage Earnings Report
MENS Jyong Biotech	N/A	$2.04 +2.0%	N/A	-95.4%	$152.05M	N/A	N/A	31	Gap Up
CRDL Cardiol Therapeutics	2.2483 of 5 stars	$1.36 +3.8%	$8.50 +525.0%	+49.1%	$151.81M	N/A	N/A	20	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHE) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alterity Therapeutics (ATHE) Competitors

ATHE vs. LENZ, AARD, MENS, CRDL, and MIST

How does Alterity Therapeutics compare to LENZ Therapeutics?

Summary

How does Alterity Therapeutics compare to Aardvark Therapeutics?

Summary

How does Alterity Therapeutics compare to Jyong Biotech?

Summary

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Summary

How does Alterity Therapeutics compare to Milestone Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alterity Therapeutics (ATHE) Competitors

ATHE vs. LENZ, AARD, MENS, CRDL, and MIST

How does Alterity Therapeutics compare to LENZ Therapeutics?

Do institutionals & insiders have more ownership in LENZ or ATHE?

Is LENZ or ATHE more profitable?

Which has higher valuation & earnings, LENZ or ATHE?

Which has more volatility & risk, LENZ or ATHE?

Do analysts rate LENZ or ATHE?

Does the media prefer LENZ or ATHE?

Summary

How does Alterity Therapeutics compare to Aardvark Therapeutics?

Do institutionals and insiders believe in ATHE or AARD?

Does the media refer more to ATHE or AARD?

Which has more volatility and risk, ATHE or AARD?

Which has better valuation & earnings, ATHE or AARD?

Is ATHE or AARD more profitable?

Do analysts rate ATHE or AARD?

Summary

How does Alterity Therapeutics compare to Jyong Biotech?

Which has more risk and volatility, ATHE or MENS?

Do analysts prefer ATHE or MENS?

Is ATHE or MENS more profitable?

Do institutionals & insiders believe in ATHE or MENS?

Which has better earnings & valuation, ATHE or MENS?

Does the media favor ATHE or MENS?

Summary

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Is ATHE or CRDL more profitable?

Which has better valuation and earnings, ATHE or CRDL?

Does the media favor ATHE or CRDL?

Which has more risk and volatility, ATHE or CRDL?

Do institutionals and insiders believe in ATHE or CRDL?

Do analysts rate ATHE or CRDL?

Summary

How does Alterity Therapeutics compare to Milestone Pharmaceuticals?

Do analysts recommend MIST or ATHE?

Does the media refer more to MIST or ATHE?

Do institutionals & insiders hold more shares of MIST or ATHE?

Which has more risk & volatility, MIST or ATHE?

Which has better valuation and earnings, MIST or ATHE?

Is MIST or ATHE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools